Placeholder Banner

BIO Comments on FDA Draft Guidance on Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications

December 18, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications, Guidance for Industry and Review Staff.

BIO appreciates the effort to update and release the guidance to inform industry, sponsors, and FDA staff and reviewers about regulatory review practices. This will support a more efficient and transparent review of new therapies. BIO provides suggestions on how to strengthen the document and communications, and ensure all stakeholders have appropriate information and resources.

 

Download Full Comments Below
BIO Comment Letter FDA Draft Guidance On Good Review Principles And Practices For NDAs And BLAs FDA-2018-D-3103
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…